Accelerating the Mission: OCRA President & CEO Audra Moran Named a Crain’ 2026 Notable Leader in Health Care
Ovarian Cancer Research Alliance (OCRA) is proud to share that President and CEO Audra Moran has been named a Crain’s New York Business 2026 Notable Leader in Health Care—an annual recognition honoring executives whose leadership, innovation, and community commitment set a high bar for the field.
Moran has led OCRA since 2010. In the years since, OCRA’s annual revenue has nearly tripled, from $7.7 million to $21.6 million, fueling the organization’s expanding mission to fight ovarian and gynecologic cancer through research, patient support, and advocacy. Under her leadership, OCRA has surpassed $140 million in research funding, grown to support 140,000 individuals annually through its programs and resources, and, as the sole dedicated voice for gynecologic cancers on Capitol Hill, helped to secure $3.8 billion in federal research and education funding.
More recently, Moran has led a significant expansion of OCRA’s reach and impact: welcoming The Clearity Foundation and the Rivkin Center for Ovarian Cancer Research into the OCRA family, extending the organization’s mission to all gynecologic cancers, and co-founding the Global Ovarian Cancer Research Consortium.
Moran spoke with Crain’s Quick Take’s Andrea Walker-Leidy about the initiatives driving OCRA’s momentum, including the Global Ovarian Cancer Research Consortium and the AI-powered research tools reshaping what’s possible for patients.
Turning Hope Into Action: OCRA Rivkin Family SummeRun Set for July 12 in Seattle
Registration is now open for the OCRA Rivkin Family SummeRun, taking place again this year at Seattle’s Seward Park on Sunday, July 12, 2026.
This year’s iconic event brings exciting new additions: official race timing (making this a qualifying race for larger events) and a brand-new SummeRun Sprinters Kids Fun Run for ages 2-9. Bring the whole family!
Early Bird pricing of $30 is available through May 31. Individuals who donate $1,000 or teams that raise $2,500 will have a name honored on the official event t-shirt (deadline: June 1). And registration is free for ovarian and gynecologic cancer survivors.
OCRA is proud to honor the Rivkin Center’s remarkable legacy of more than 30 years of channeling community energy into vital research for everyone impacted by ovarian cancer.
Register today!
Upcoming Support & Education Sessions
OCRA delivers diverse support and education programming for those impacted by gynecologic cancer, including information-packed webinars, workshops, roundtables, and supportive community-building sessions. Highlighted below are some of our programs this month.
Staying Current: Endometrial Cancer Treatment Updates
May 5 at 11AM ET | Register
Staying Connected: Book Club
The Extraordinary Life of Sam Hell by Robert Dugoni
May 12 at 3PM ET | Register
Roundtable: Nutrition for the Menopause Transition and Beyond
May 20 at 12PM ET | Register
Staying Connected: Express Yourself
“Joyous Me”
May 21 at 3PM ET | Register
OCRA’s Patient Support and Education programs are generously sponsored by AbbVie, AstraZeneca, Genentech, Genmab, GSK, Merck, PMV Pharma, and the Shirley Z. Johnson Trust.
OCRA’s Advocate’s Corner
With appropriations season in full swing, some portions of the health spending request in the President’s FY2027 budget proposal represent a step in the right direction for the ovarian and gynecologic cancer community.
Meanwhile, your actions are already making an impact: Dear Colleague letter support for the Ovarian Cancer Research Program grew from 75 U.S. House Representatives to 106 after our Spring Advocacy Day push.
Read the full update in this month’s Advocate’s Corner.
Rivkin Ovarian Cancer Research Symposium: Now Accepting Abstract Submissions
The 16th Biennial Rivkin Ovarian Cancer Research Symposium comes to Philadelphia, October 16–18, 2026, and researchers are now invited to submit abstracts for consideration as a talk or poster presentation.
The program will kick off with a patient advocacy panel. Keynote speakers are Ronny Drapkin, MD, PhD and Daniela Matei, MD.
Topics span the landscape of ovarian cancer science, including prevention and early detection, new therapeutic approaches, immunotherapy, drug resistance, and health disparities.
